Elizabeth Holmes documentary reaches No. 1 at the box office, a first for nonfiction since "Fahrenheit 9/11"

LOS ANGELES — "You Can See Everything," the A24 documentary that follows Theranos founder Elizabeth Holmes through the weeks before she reported to federal prison, finished first at the North American box office over the weekend of Oct. 30 to Nov. 1, narrowly ahead of the Warner Bros. horror title "Clayface." It was the film's first weekend at No. 1 after holding at No. 2 for its first two weeks in wide release, and trade coverage described it as the first nonmusic documentary to win a weekend since Michael Moore's "Fahrenheit 9/11" in 2004.

Studio estimates circulated that Sunday put the film's weekend gross at roughly $10.6 million against about $10.4 million for "Clayface," a margin of some $200,000. Final tallies compiled by the box-office tracking site The Numbers later put the confirmed weekend total at $11.4 million from 3,243 theaters, lifting the film's domestic cumulative gross to roughly $64.7 million against a reported production budget of about $7 million, which A24 has said cost less than $10 million to market.

From 855 screens to more than 3,000

Directed by Nathan Fielder and Lance Oppenheim, "You Can See Everything" opened Oct. 16 in just 855 theaters and grossed $15.6 million its first weekend, the strongest documentary debut since 2013's "One Direction: This Is Us" and, outside concert films, the best since "Fahrenheit 9/11" set the all-time unadjusted documentary opening record of $23.9 million. A24 has said the opening weekend included more than 2,000 sold-out shows. The distributor, which released the film through its own theatrical pipeline rather than a partner studio, expanded it to 2,655 locations the following weekend and to 3,243 by its third, according to A24's official page for the film.

The run has already pushed the film past "Becoming Led Zeppelin," last year's top-grossing documentary at roughly $16 million, and past older benchmarks such as "An Inconvenient Truth" ($49 million) and "Bowling for Columbine" ($58 million), a point the trade site WorldOfReel flagged when it noted that no nonmusic documentary had led a weekend chart since "Fahrenheit 9/11" more than two decades earlier. Whether it can approach "March of the Penguins" ($133 million) or "Fahrenheit 9/11" itself ($222 million) remains an open question as its theater count now begins to contract.

A film built on a change of mind

The documentary was shot largely in secret over roughly three years and centers on the 34 days before Holmes began serving an 11-year, three-month sentence for defrauding Theranos investors. The Securities and Exchange Commission had charged Holmes and the company in 2018 with raising more than $700 million from investors through years of misrepresentations about Theranos's blood-testing technology; she was later convicted on separate criminal fraud charges. Fielder has said his view of Holmes shifted once he began filming with her.

"When I started the project, Elizabeth seemed black and white to me," Fielder told W Magazine. "In my mind, she was guilty. But I was very interested in her and her situation. Curiosity drove me."

At the film's New York Film Festival premiere, Fielder described the unease of sitting across from his subject, telling an audience that he would catch himself finding Holmes "so genuine at times" before reminding himself, as he put it to Variety, that "I know she's a liar." Reviewers have largely agreed the resulting film resists a simple verdict; it carries a 99 percent critics' score on Rotten Tomatoes, unusually high even by A24's documentary standards.

A rare win for theatrical nonfiction

The box-office run matters beyond one unusual weekend. Documentary features have struggled for theatrical attention for years, squeezed by streaming and the retreat of mid-size specialty distributors, and the Motion Picture Association has cited the film's path from a secret Telluride Film Festival screening in September to a wide commercial release as one of the more unusual theatrical stories of the year. For exhibitors, who have leaned on documentaries, concert films and re-releases to fill screens during a thinner fall slate, a $64 million-plus nonfiction hit is a meaningful data point heading into the holiday corridor.

A24 benefits most directly. The studio, known for prestige horror and awards contenders, has rarely had a documentary perform at this scale, and the film's cost-to-gross ratio — a $7 million budget against a box office haul already nine times that figure — makes it one of the most profitable theatrical releases of the specialty distributor's history to date, even before any streaming or awards-season revenue. Warner Bros., whose "Clayface" placed second after a $200,000 gap, continues to benefit from that film's own strong hold, which crossed $80 million domestically in the same stretch.

What comes next

"You Can See Everything" is now heading into its fourth weekend with a shrinking theater footprint, the typical pattern once a specialty release has exhausted its widest rollout, and distributors will be watching whether word of mouth can sustain per-theater averages as screens are trimmed. The film is also emerging as an awards-season talking point, with Fielder and Oppenheim's hybrid approach — filming Holmes as a cooperative subject rather than relying on archival material, as prior dramatizations such as Hulu's "The Dropout" did — fueling continued conversation ahead of likely documentary-category contention. A24 has not announced a streaming date, though the studio's past releases have typically migrated to HBO Max several months after their theatrical run ends.

For now, the film stands as a reminder that an unusually specific true-crime subject, backed by festival buzz and a modest budget, can still outperform expectations in a theatrical marketplace that has largely written off nonfiction film as a box-office draw.